Study of nerandomilast for people with systemic sclerosis
Part of Skin clinical trials.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have systemic sclerosis.
- You have either limited or diffuse systemic sclerosis that is active.
- Your lung function test (FVC) is at least 45% of normal.
- Your lung diffusing capacity (DLCO) is at least 25% of normal.
- Your disease began within the last 7 years.
- If you are a woman able to have children, you must use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.